Nicholas Saraceno, Editor

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

A seminar shares key observations and learnings from the first round of direct price negotiations.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Brett Casper explores the marketplace complexities that manufacturers face regularly.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes potential availability challenges brought on by supply chain obstacles.

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares insights on how sustainability has evolved from a compliance requirement to a key business strategy, driving operational efficiencies, innovation, and long-term growth.

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, comments on the steps needed to achieve Drug Supply Chain Security Act compliance.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, describes his day-to-day workflow at Morris & Dickson, and how it supports the efficiency and reliability of the distributor’s operations.

Will Robinson, program director, LogiPharma, shares how in-depth conversations—not AI—drive the research behind one of the industry's most anticipated annual agendas.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, explains how he foresees the future of the organization, along with the role he hopes to play in shaping its direction.

Will Robinson, program director, LogiPharma, explains how artificial intelligence and sustainability are driving a clear shift in priorities across the pharmaceutical supply chain.

The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, emphasizes the importance of the separation of core business and foundation, the value of patient empowerment, and the impact of digital innovation.

Will Robinson, program director, LogiPharma, reveals why the conference will be moved to Vienna moving forward.

One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.

Access USA converges in Philadelphia to explore new—and needed—solutions to boost patient outcomes.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, provides an update on where the healthcare industry currently stands in terms of compliance with price transparency regulations, and what steps need to be taken to achieve full compliance.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, discusses the biggest challenges healthcare organizations currently face in terms of price transparency.